Nasdaq:MESO

Ryoncil is Now Available for Purchase in the United StatesRyoncil is Now Available for Purchase in the United States

Ryoncil is Now Available for Purchase in the United States

March 26, 2025 20:19 ET  | Source: Mesoblast Limited NEW YORK, March 26, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO;…

4 weeks ago
Mesoblast Added to S&P/ASX 200 INDEXMesoblast Added to S&P/ASX 200 INDEX

Mesoblast Added to S&P/ASX 200 INDEX

March 06, 2025 18:54 ET  | Source: Mesoblast Limited NEW YORK, March 06, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO;…

2 months ago
Dr. Gregory George MD PhD Joins Mesoblast BoardDr. Gregory George MD PhD Joins Mesoblast Board

Dr. Gregory George MD PhD Joins Mesoblast Board

February 23, 2025 18:33 ET  | Source: Mesoblast Limited NEW YORK, Feb. 23, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO;…

2 months ago
Mesoblasts RYONCIL is the First U.S. FDA-Approved Mesenchymal Stromal Cell (MSC) TherapyMesoblasts RYONCIL is the First U.S. FDA-Approved Mesenchymal Stromal Cell (MSC) Therapy

Mesoblasts RYONCIL is the First U.S. FDA-Approved Mesenchymal Stromal Cell (MSC) Therapy

December 18, 2024 19:08 ET  | Source: Mesoblast Limited RYONCIL (remestemcel-L) is the first MSC product approved by FDA for…

4 months ago
Revascor Improves Survival and Reduces Major Morbidity in High-Risk Ischemic Heart Failure Patients With InflammationRevascor Improves Survival and Reduces Major Morbidity in High-Risk Ischemic Heart Failure Patients With Inflammation

Revascor Improves Survival and Reduces Major Morbidity in High-Risk Ischemic Heart Failure Patients With Inflammation

Phase 3 trial results published in European Journal of Heart Failure identify key target population for Mesoblast allogeneic cell therapy…

5 months ago